drugset / Trial / NCT05750875

Gabapentin Versus Loratadine in Uremic Pruritus

NCT05750875

Phase 4 Completed 64 enrolled King Edward Medical University
RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to compare the efficacy of gabapentin with loratadine in reducing the severity of uremic pruritus in patients of chronic kidney disease and to compare the side effects of both drugs. The main questions it aims to answer are: * Which drug (gabapentin versus loratadine) is more effective in reducing the severity of uremic pruritus? * Which drug (gabapentin versus loratadine) has fewer side effects? Participants were divided into two groups.Group A received loratadine 10mg daily and group B received gabapentin 100mg daily. Both groups were given treatment for 4 weeks. * Participants were asked to grade the severity of pruritus on a numerical rating scale and also answer the Dermatology Life Quality Index Questionnaire (DLQI) * Participants were also asked to report any side effects, if occurred. Researchers compared both groups with regards to improvement in pruritus severity, DLQI score and side effects.

Timeline

Start
2022-05-01
Primary completion
2022-10-31
Completion
2022-10-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Gabapentin Small molecule 100 mg Oral
Comparator Loratadine Small molecule 10 mg Oral